Validation of a bioanalytical HPLC–UV method to quantify Α‐Bisabolol in rat plasma applied to pharmacokinetic pilot study with the drug nanoemulsion

• Published in: Biomedical chromatography 2024-09, Vol.38 (9), p.e5949-n/a
• Main Authors: Hora Borges, Matheus Antônio, Santos de Araújo, Jackeline Marley, Pereira, Laiz Campos, Santos, Luisa Oliveira, Santos, Valdeene Vieira, Santos Santana, Lorena, Souza Siqueira Quintans, Jullyana, Rodrigues Marcelino, Henrique, Rambo, Douglas Fernando, Azeredo, Francine Johansson
• Format: Article
• Language: English
• Subjects: bioanalytical validation; HPLC–UV; nanoemulsion; pharmacokinetics; rat plasma; α‐bisabolol
• ISSN: 0269-3879; 1099-0801; 1099-0801
• DOI: 10.1002/bmc.5949

α‐Bisabolol (α‐BIS) is a sesquiterpene alcohol present in chamomile essential oil [Chamomilla recutita (L.) Rauschert]. Despite its numerous pharmacological effects, its pharmacokinetics remain understudied. An analytical method capable of quantifying α‐BIS in plasma is crucial to enable pharmacokinetic analysis. Presently, only one study has quantified it using mass spectrometry. Administering α‐BIS requires a nanoemulsion for intravenous injection. This study aimed to develop and validate a bioanalytical method using high‐performance liquid chromatography with an ultraviolet detector to quantify α‐BIS in rat plasma. The method employed acetonitrile and ultrapure water (80:20, v/v) as the mobile phase, with a flow rate of 1 ml/min and concentrations ranging from 465 to 29.625 μg/ml. All US Food and Drug Administration‐designated assays were successful, indicating the method's precision, accuracy, sensitivity and linearity in determining α‐BIS in rat plasma. The developed nanoemulsion, assessed through dynamic light scattering analysis, the ensemble collection of particles and polydispersity index evaluation, proved safe and effective for intravenous administration. The pharmacokinetic parameters such as volume of distribution, clearance and half‐life indicated that α‐BIS tends to persist in the body. This study provides a foundation for further research to explore α‐BIS's potential pharmaceutical applications in the future.